Co-Authors
This is a "connection" page, showing publications co-authored by Giovanni Sotgiu and Simon Tiberi.
Connection Strength
5.361
-
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. Int J Infect Dis. 2021 Dec; 113 Suppl 1:S96-S99.
Score: 0.467
-
COVID-19 and tuberculosis-threats and opportunities. Int J Tuberc Lung Dis. 2020 08 01; 24(8):757-760.
Score: 0.448
-
Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs. Int J Infect Dis. 2019 Mar; 80S:S68-S72.
Score: 0.403
-
Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis. 2018 07; 18(7):e183-e198.
Score: 0.380
-
Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB". Int J Infect Dis. 2018 03; 68:122-124.
Score: 0.380
-
Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress! EBioMedicine. 2018 03; 29:11-12.
Score: 0.377
-
Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis? Int J Infect Dis. 2017 12; 65:133-134.
Score: 0.370
-
Post-implementation blues: the unfulfilled potential of Xpert. Int J Tuberc Lung Dis. 2017 10 01; 21(10):1073.
Score: 0.368
-
Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Bras Pneumol. 2019 Apr 25; 45(2):e20180324.
Score: 0.205
-
Defining the best regimen to treat isoniazid-resistant tuberculosis. Lancet Respir Med. 2018 04; 6(4):233-235.
Score: 0.190
-
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. J Bras Pneumol. 2018 Apr; 44(2):153-160.
Score: 0.190
-
Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis. Eur Respir J. 2018 03; 51(3).
Score: 0.190
-
Different disease, same challenges: Social determinants of tuberculosis and COVID-19. Pulmonology. 2021 Jul-Aug; 27(4):338-344.
Score: 0.116
-
Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021. Pulmonology. 2021 Mar-Apr; 27(2):94-96.
Score: 0.114
-
Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned. Lancet Infect Dis. 2019 01; 19(1):3-4.
Score: 0.100
-
Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis. Lancet Infect Dis. 2018 05; 18(5):480-481.
Score: 0.094
-
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. J Thorac Dis. 2017 Jul; 9(7):2093-2101.
Score: 0.090
-
Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. Eur Respir J. 2021 11; 58(5).
Score: 0.061
-
Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. Pulmonology. 2021 May-Jun; 27(3):248-256.
Score: 0.058
-
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. Pulmonology. 2021 Mar-Apr; 27(2):151-165.
Score: 0.058
-
Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). Eur Respir J. 2020 10; 56(4).
Score: 0.057
-
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. Emerg Infect Dis. 2020 11; 26(11):2709-2712.
Score: 0.056
-
On tuberculosis and COVID-19 co-infection. Eur Respir J. 2020 08; 56(2).
Score: 0.056
-
Tuberculosis in the time of COVID-19: quality of life and digital innovation. Eur Respir J. 2020 08; 56(2).
Score: 0.056
-
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020 07; 56(1).
Score: 0.056
-
Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices? J Bras Pneumol. 2019 04 25; 45(2):e20190043.
Score: 0.051
-
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review. Eur Respir J. 2018 07; 52(1).
Score: 0.048
-
ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. Eur Respir J. 2018 05; 51(5).
Score: 0.048
-
Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond. Pulmonology. 2018 Mar - Apr; 24(2):132-141.
Score: 0.047
-
Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017 11; 50(5).
Score: 0.046
-
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis. Emerg Infect Dis. 2017 10; 23(10).
Score: 0.046
-
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J. 2017 05; 49(5).
Score: 0.045
-
Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017 03; 49(3).
Score: 0.044
-
Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. Int J Mol Sci. 2017 Feb 07; 18(2).
Score: 0.044